The clinical need to help treat oral mucositis


Prevalence and impact

Oral mucositis is a frequent complication of chemotherapy and/or radiation therapy1,2

  • Oral mucositis can affect a majority of patients undergoing radiation and/or chemotherapy
  • Over 40% of cancer patients undergoing conventional chemotherapy develop oral mucositis
  • 97 to 100 percent of radiation patients experience oral mucositis3

Oral mucositis can lead to significant health complications, including2:

  • The need for analgesics or opioid analgesics for pain relief
  • The possibility of missed cancer therapy doses, dose interruptions, dose limitations, and treatment failure
  • Increase in the risk of significant infection
    • However, NeutraSal is not intended to treat infection

INDICATIONS

NeutraSal® is indicated for dryness of the mouth (hyposalivation, xerostomia) and dryness of the oral mucosa due to drugs that suppress salivary secretion.

IMPORTANT SAFETY INFORMATION

  • Not intended to prevent xerostomia or oral mucositis.
  • Patients should avoid eating or drinking for at least 15 minutes after use
  • Solution should not be swallowed but be spit out.
  • Not intended for systemic use to treat any diseases of the throat or upper gastrointestinal tract
  • Not intended for use as an antacid
  • No adverse events anticipated if swallowed accidentally
  • Contains sodium; Patients restricted to a low-sodium diet should consult their physician before use.
  • No known interactions with medicinal or other products

Please click here for Instructions for Use.

References: 1. Peterson DE. New strategies for management of oral mucositis in cancer patients. J Support Oncol. 2006;4(2 Suppl 1):9-13. 2. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201-2205. 3. Basu T, Laskar SG, Gupta T, Budrukkar A, Murthy V, Agarwal JP. Toxicity with radiotherapy for oral cancers and its management: a practical approach. J Cancer Res Ther. 2012;8(6):72-84.

OraPharma, a division of Bausch Health Companies Inc. or its affiliates.
Copyright © 2021 Bausch Health Companies Inc. or its affiliates.   NSL.0015.USA.21
CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

See More

INDICATIONS

NeutraSal® is indicated for dryness of the mouth (hyposalivation, xerostomia) and dryness of the oral mucosa due to drugs that suppress salivary secretion.

IMPORTANT SAFETY INFORMATION

  • Not intended to prevent xerostomia or oral mucositis.
  • Patients should avoid eating or drinking for at least 15 minutes after use
  • Solution should not be swallowed but be spit out.
  • Not intended for systemic use to treat any diseases of the throat or upper gastrointestinal tract
  • Not intended for use as an antacid
  • No adverse events anticipated if swallowed accidentally
  • Contains sodium; Patients restricted to a low-sodium diet should consult their physician before use.
  • No known interactions with medicinal or other products

Please click here for Instructions for Use.